Actualización sobre la vacunación contra el dengue por parte del NIP

CTAI-HPV subgroup HPV VACCINATION MEETING IN PREPARED PERSONS: PROTOCOL AND IMPLEMENTATION Taking into account the morbidity profile of PrEP users (with increased vulnerability to sexually transmitted infections), as well as the efficacy of the vaccine in reducing lesions related to HPV genotypes, it was unanimously recommended to extend HPV vaccination to PrEP users aged 15-45 years, according to the guidelines below:

Vacunación contra el dengue en Brasil